Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
INTREPID Alliance
Indianapolis, Indiana, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
INTREPID Alliance publishes biannual landscape analyses summarizing the global pipeline of antiviral candidates for pathogens with pandemic potential. These reports identify promising clinical and preclinical compounds across 13 viral families, highlight R&D gaps, and support the "100 Days Mission" to have at least 25 antivirals ready for Phase II/III trials by 2026. The alliance’s work is advisory and non-commercial in nature
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculeBiologic
- Industry
- Consulting
02
Partnerships
AbbVieAmgenGilead SciencesJohnson & Johnson (Janssen)NovartisRocheTakedaBill & Melinda Gates FoundationUniversity of Cape Town
Beyond the preview
Go deeper on INTREPID Alliance.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INTREPID Alliance.